Five Billion-Dollar Deals in 45 Days: Inside the Cardiac Monitoring Gold Rush with Ken Nelson

In this episode of The Crux of Cardio, Jordan Burgin sits down with Ken Nelson, one of the most experienced commercial leaders in cardiac digital health.
Ken helped scale commercial teams at iRhythm, BioTelemetry/CardioNet, and Bardy Diagnostics, three of the defining names in ambulatory cardiac monitoring. He shares the inside story behind the 2020–2021 cardiac monitoring M&A wave, including Philips’ acquisition of BioTelemetry, Hillrom’s acquisition of BardyDx, and Boston Scientific’s acquisition of Preventice.
The conversation also covers the Medicare reimbursement shock that nearly derailed the Bardy transaction, the court decision that forced Hillrom to complete the deal, and the personal loss that now shapes Ken’s work as an investor, board member, and mentor across cardiac and EP startups.

Key Topics:

• The 45-day acquisition wave: Philips/BioTelemetry, Boston Scientific/Preventice, and Hillrom/Bardy

• How a Medicare reimbursement error nearly killed the Bardy acquisition

• Ken's people-first commercialisation playbook for medtech startups

• The personal tragedy that made fighting heart disease his life's mission

• Ken's current thesis at Nelson Jennings Ventures and his portfolio companies

Related Insights:

• Why angel investors and family offices matter more than ever for early-stage cardiac startups

• HeartBeam's credit-card-sized 12-lead ECG and the future of at-home heart attack detection

• How Echo IQ is applying AI to echocardiography to detect aortic stenosis and heart failure

• Why wearable therapeutics like StimCardio will disrupt the standard of care in cardiac arrhythmia

Core Challenges:

• Remote patient monitoring reimbursement codes haven't kept pace with multi-sensor, multi-condition wearable devices, creating a bottleneck for commercialisation

• Cardiac startups need tighter collaboration between the FDA, CMS, payers, and industry accelerators to drive faster adoption of emerging technologies

• Series A funding goalposts have shifted: earlier clinical data is now expected, making angel investors and family offices critical for bridging the gap

🎧 Tune in now to hear how Ken Nelson went from a finance cubicle to building the commercial engine behind cardiac monitoring's biggest exits, and what he's betting on next.

The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.

To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A big thank you to our sponsors on this season of the podcast;

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠